

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

NCT07064759

Status	RECRUITING
Phase	Phase 3
Sponsor	4D Molecular Therapeutics
Enrollment	480 participants

Key Eligibility Criteria

Inclusion (8)

- e50years of age at time of consent
 - MNV secondary to nAMD with IVT anti-VEGF treatment history in the study eye, defined as EITHER:
 - Treatment naïve, i.e. no prior IVT anti-VEGF therapy OR
 - Previously treated with no more than 4 IVT anti-VEGF injections due to nAMD and received diagnosis of nAMD no more than 6 months prior to the Screening Visit AND documented evidence of anatomical improvement and visual stability/improvement in response to previous IVT anti-VEGF treatment, as determined by the Investigator
 - Active subfoveal MNV or juxtafoveal/ extrafoveal MNV with a subfoveal component (where activity is defined as evidence of SRF, IRF, subretinal hyperreflective material, or leakage) identified by fluorescein angiography (FA) or spectral domain optical coherence tomography (SD-OCT) , in the study eye, at the Screening Visit confirmed by the Reading Center
- ... and 3 more (see full listing online)

Exclusion (12)

- Ocular Conditions:
 - MNV due to causes other than nAMD in either eye (Fibrosis, atrophy, or subretinal hemorrhage in the foveal central subfield (1 mm diameter)
 - History of retinal detachment in the study eye
 - History of or presence of active inflammation in either eye
 - Glaucoma or intraocular hypertension requiring more than 2 topical medications for control
- ... and 7 more (see full listing online)

Locations (43 total)

Barnet Dulaney Perkins Eye Center, Sun City, Arizona, United States
Retina Associates, Tucson, Arizona, United States
Retinal Diagnostic Center, Campbell, California, United States
... and 40 more locations